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We used hospital antibiograms to assess predominant
pathogens and their patterns of in vitro antimicrobial resist-
ance in central Illinois, USA. We found a lack of information
about national guidelines for in vitro antimicrobial suscepti-
bility testing and differences in interpretation among labora-
tories in the region.
A
number of databases are available in the United States
to monitor antimicrobial resistance at a national level
(1). The academic and educational value of these databas-
es is particularly useful for microbiologists and infectious
disease clinicians. However, databases are unlikely to
prove useful in improving antimicrobial use in the commu-
nities for a number of reasons: 1) most antimicrobial drug
prescriptions in the community are written by primary care
physicians, 2) most primary care physicians do not use
these resources, and 3) industry-generated data are often
used to highlight a particular antimicrobial drug. Even for
infectious disease clinicians, national databases serve as a
general guide, particularly during the initial or presump-
tive phase of antimicrobial therapy when culture results are
not available.
For tertiary care/referral hospitals, a substantial per-
centage of patients are transferred from community hospi-
tals outside the local area. Under these circumstances,
resistance surveillance data from these areas would help
select presumptive therapy or change existing therapy.
Very often, when patients have been treated with empiric
antimicrobial drugs, the culture results at the tertiary care
institutions may be negative or do not detect the infecting
organism. To overcome these difficulties and improve the
outcome of serious infections in the referral area for our
institution, we monitored resistance patterns in the region
and generated a regional antibiogram, which will be shared
with all participating hospitals.
The Study
A packet was sent to the clinical microbiology labora-
tories of the 77 hospitals in the area. It included a letter
describing the project, a questionnaire on hospital charac-
teristics and laboratory testing methods, and a request for
existing antibiograms from the most recent period for
which completed data were available. We used only antibi-
ograms from January 2001 to June 2002. From the antibi-
ograms, the numbers of isolates tested and number of
susceptible isolates were added for each antimicrobial
agent from all hospitals for each region (Appendix Table 1,
available from http://www.cdc.gov/ncidod/EID/vol11
no08/05-0135_app1.htm) and for all regions combined.
The proportion of responding hospitals was 53%; all
major academic centers participated. Data from 10 hospi-
tals were excluded, 7 because the aggregated antibiograms
did not include the number of isolates tested and 3 because
the antibiogram data predated January 2001. Thirty-one
hospitals that were included in the final analysis represent-
ed the 4 regions as follows: 16 (42%) of 38 hospitals in the
central region, 6 (43%) of 14 in the west, 4 (40%) of 10 in
the south, and 5 (33%) of 15 in the southwest. Of the hos-
pitals included, 16% did not send a cumulative antibi-
ogram but instead sent their data as a monthly report for a
period from 3 months to 1 year. Our research team gener-
ated cumulative antibiograms for these hospitals.
The proposed guidelines for analyzing and presenting
cumulative antimicrobial susceptibility data were published
by the Clinical and Laboratory Standards Institute (former-
ly NCCLS) in 2002. The M39-Adocument provides a stan-
dardized means of data extraction for all drugs tested and
outlines the most appropriate way to present the data (2).
In our discussions with laboratory personnel, we found
that many laboratories are unaware of these guidelines,
and laboratories that use the document find that adhering
to all recommendations is difficult. Many laboratories lack
a microbiology supervisor with insight into the clinical rel-
evance of the results they generate. For example, a labora-
tory reported 4% vancomycin resistance in Streptococcus
pneumoniae, but the laboratory staff was not able to
explain this finding or recognize the clinical implications.
Also 2 of the hospitals reported 2 vancomycin-intermedi-
ate Staphylococcus aureus in their antibiogram. However,
the isolates were not available for verification, and the lab-
oratory staff was not aware of the implications of this find-
ing. The staff did not know that such findings should be
reported to the Illinois Department of Public Health and
the Centers for Disease Control and Prevention.
In all regions, Escherichia coli was the most common-
ly isolated organism, followed by S. aureus. Coagulase-
negative staphylococci, Pseudomonas aeruginosa, and
Enterococcus faecalis were among the 5 most frequently
reported species (Appendix Tables 1 and 2 [available from
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app2.htm]). The 10 most frequently reported species in our
study are generally comparable to those found in the SEN-
TRY survey conducted by Pfaller et al. (3).
Of the S. aureus isolates tested in the central, west,
south, and southwest regions, 27%, 53%, 34%, and 42%,
respectively, were resistant to methicillin. Of the hospitals
that reported speciation of enterococci, E. faecalis was sus-
ceptible to vancomycin at 91%–99%. The vancomycin
resistance among E. faecium was 32%–73%. However,
hospitals from the southwest area reported enterococci
other than E. faecalis as  Enterococcus spp. only. The
unusually low susceptibility of E. faecium in our study
may be attributed to specimen duplication.
In the central Illinois region, the susceptibility of S.
pneumoniae to penicillin was 64%–75%, and 52%–77% of
isolates were susceptible to erythromycin. The susceptibil-
ity of common gram-positive bacteria in our study appears
to be lower than reported national averages (3). Although
antibiogram surveillance and active surveillance yield
comparable results (4), national data may not be directly
comparable to our findings because national data used for
comparison results from active surveillance with different
reporting periods. In addition, geographic factors must be
taken into consideration (4–7).
Conclusions
In spite of expertise and resources available in the
United States, the use of antimicrobial drugs in day-to-day
practice is suboptimal and directly responsible for mul-
tidrug resistance in a number of common pathogens. The
factor that converts antimicrobial therapy from “empiric” to
“rational” is in vitro susceptibility testing and reporting.
However, if these tests are either not conducted or conduct-
ed poorly, they are not useful clinically and may create a
false sense that therapy is rationally guided. Given the dif-
ferences and shortcomings we reported among laboratories
in a region, national recommendations are either unknown
or not followed. Use of expertise, cooperation, and collab-
oration at the regional levels may be the simplest and most
useful public health measures to optimize the usefulness of
diagnostic microbiology in managing infectious diseases.
Antimicrobial drug use guidelines, if they are based on con-
sistent, reproducible, and comparable data between differ-
ent laboratories, will produce better outcomes. A master
antibiogram for a region would allow a tertiary care institu-
tion to consider resistance patterns in hospitals referring
patients and to select appropriate “presumptive” antimicro-
bial therapy or change drugs in nonresponding patients. We
hope that the concept of “empiric antimicrobial therapy”
would be changed to that of “presumptive antimicrobial
therapy” based on host factors, common pathogens, and
known susceptibility patterns in any given region.
This study has helped us identify serious shortcomings
in susceptibility testing methods and reporting, and we hope
to address these issues through a regional advisory group.
Even if following all the recommendations in M39-A are
not possible, the second best option may be to have all
regional laboratories adhere to the same subset of recom-
mendations. Antimicrobial resistance data generated by this
approach will have better day-to-day application than will
data generated by large national databases. The data will
also be useful in monitoring resistance trends in a region
over time and assessing the effects of interventions to
reduce antimicrobial resistance. We recognize the shortcom-
ings of the data presented in this article but believe them to
be the basis for improvement at a fundamental level.
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